Shares of Graphite India and Epigral came under pressure on Monday after the companies reported weak earnings for the quarter ended September 30, 2025, while Krsnaa Diagnostics rose on strong results.
Graphite India settled 7.23 percent lower at Rs 535.50 on the NSE after the company posted a 60.5 percent decline in consolidated net profit to Rs 77 crore for the September quarter, compared with Rs 195 crore in the year-ago period. The fall in profit was attributed to lower electrode prices and weaker operating margins.
Epigral shares closed 7.65 percent down at Rs 1,522 apiece after the chemical manufacturer reported a 37 percent year-on-year drop in net profit to Rs 51.2 crore from Rs 81.3 crore. Revenue from operations slipped 6.2 percent to Rs 587.3 crore from Rs 626 crore a year earlier.
Krsnaa Diagnostics shares advanced 8 percent to close at Rs 781.50 on the NSE after the company reported a 22 percent rise in net profit to Rs 23.94 crore for the September quarter.
According to data compiled by LSEG, the stock has a “Buy” rating on average from three analysts, with a median price target of Rs 1,127. Around 5.66 lakh shares changed hands on the exchange, sharply higher than the 30-day average volume of 71,926 shares. Year-to-date, the stock is down 7.5 percent.
(Reuters Inputs)
Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
